Overview / Abstract: |
FDA-approved agents that target vascular endothelial growth factor (VEGF) constitute important elements of optimal management of AMD. Prior authorization (PA) requirements limit patient access to these therapies. Navigating the PA process can be frustrating for patients, and may result in treatment abandonment leading to suboptimal outcomes. Hence, there is a need for patients to become advocates of their treatment choice. The final module of this CME Outfitters Snack series describes step therapy policies and their implications for the patient, with the goal of educating clinicians on the increased risks of these policies, including the possibility of increased medical costs and worsening of the disease, so that they can pass this knowledge on to their patients with AMD and work together to navigate through the PA process. |
Expiration |
Nov 21, 2020 |
Discipline(s) |
Nurse Practitioner , Nursing CNE, Optometry / Ophthalmology CE, Pharmacy CPE, Physician CME, Physician Assistant CME |
Format |
Online, Webinar / Webcast / Video |
Credits / Hours |
0.25 AMA PRA Category 1 Credit(s)™/contact hours/CEUs |
Accreditation |
ACCME, AANP, ABO, MACRA, ACPE, AAPA, RCPSC |
Presenters / Authors / Faculty |
Darius M. Moshfeghi, MD Derek van Amerongen, MD, MS |
Sponsors / Supporters / Grant Providers |
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. |
Keywords / Search Terms |
CME Outfitters, LLC optometry, ophthalmology, retinal, macular degeneration, AMD Free CE CME |